Anacor’s Tavaborole May Lag Valeant’s Competing Antifungal In Both Efficacy And Approval Time
This article was originally published in The Pink Sheet Daily
Executive Summary
Anacor released positive top-line Phase III data for the most advanced of its boron-based anti-infectives, the antifungal tavaborole, but the results weren’t good enough for some shareholders who were looking for the compound to best Valeant’s antifungal, currently pending at FDA with a May action date.